Fallopian Cancer

Fallopian cancer, a rare but aggressive form of gynecological cancer, has long presented a significant challenge for healthcare providers and patients alike. However, the emergence of a novel class of therapeutics, known as poly (ADP-ribose) polymerase (PARP) inhibitors, has opened up new avenues for the treatment of this disease. At Alfa Cytology, we provide PARP inhibitor development services for the fallopian cancer therapy.

PARP as a Therapeutic Target for Fallopian Cancer

PARP is crucial for repairing single-strand breaks in DNA. In fallopian cancer cells, particularly those with rapid proliferation, effective DNA repair is essential for survival. Fallopian tube cancer often presents with genetic mutations, especially in BRCA1 and BRCA2 genes, which are vital for homologous recombination repair. These mutations lead to an increased reliance on PARP for DNA repair, making these tumors particularly vulnerable to PARP inhibition.

Fig. 1 PARP inhibitors in fallopian cancer. (Hirschl N., et al. 2024)

PARP Inhibitor Development for Fallopian Cancer

PARP inhibitors, such as olaparib and niraparib, have shown significant efficacy in treating fallopian cancer, especially in patients with BRCA mutations. Resistance to PARP inhibitors can occur, necessitating further research to understand the underlying mechanisms. Combination therapies, such as pairing PARP inhibitors with chemotherapy or immunotherapy, are being explored to enhance efficacy and overcome resistance.

PARP Inhibitor	Combination Therapy	NCT	Phase
Talazoparib	Hsp90 Inhibitor, AT13387	NCT02627430
Talazoparib	BET Inhibitor, ZEN003694	NCT05071937
Olaparib	CTLA-4 Inhibitor, Tremelimumab	NCT02571725
Veliparib	ABT-888	NCT00526617

Our Services

At Alfa Cytology, our multifaceted expertise in PARP biology, drug development, and biomarker discovery positions them as a valuable partner in accelerating the advancement of novel PARP inhibitor-based therapies for fallopian cancers. Our services leverage cutting-edge technologies and innovative platforms to accelerate PARP inhibitor development.

Small Molecule Inhibitors Development

Peptide Inhibitor Development

Advanced Biomarker Identification

High-Throughput Screening (HTS)

Structure-Based Drug Design (SBDD)

Preclinical Modeling and Screening

Our Fallopian Cancer Modeling Services

Models	Descriptions
Traditional 2D Cell Cultures	HTB 76 Cell Line
3D in Vitro Tissue-Engineering	3D Modeling of Fallopian Tube
In Vivo Models	Transgenic Murine Model Patient-Derived Xenograft Murine Model

At Alfa Cytology, we are committed to advancing the field of fallopian cancer treatment through the development of cutting-edge PARP inhibitor therapies. If you are interested in exploring our services or collaborating on PARP inhibitor research, please don't hesitate to contact us. We are eager to discuss how we can support your research efforts and contribute to the ongoing progress in fallopian cancer care.

Reference

Hirschl N., Leveque. W., and et al. PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer. Cancers. 2024, 16, 932.

For research use only. Not intended for any clinical use.